Opko Health Inc. (NASDAQ:OPK) shares gapped up prior to trading on Monday . The stock had previously closed at $2.63, but opened at $2.69. Opko Health shares last traded at $2.74, with a volume of 5082601 shares traded.
Several research analysts have weighed in on the company. Zacks Investment Research cut Opko Health from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. ValuEngine raised Opko Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, Barrington Research reaffirmed a “buy” rating and set a $7.00 price target on shares of Opko Health in a research report on Monday, November 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $9.50.
The stock has a market cap of $1.58 billion, a P/E ratio of -9.45 and a beta of 2.09. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.91 and a quick ratio of 0.78.
In related news, CEO Phillip Md Et Al Frost acquired 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 9th. The shares were acquired at an average price of $3.65 per share, with a total value of $36,500.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $11,201,671.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have purchased a total of 650,000 shares of company stock worth $2,104,100 in the last three months. 42.74% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Opko Health by 36.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,049 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 6,097 shares in the last quarter. Diversified Trust Co purchased a new position in Opko Health during the fourth quarter valued at $30,000. FDx Advisors Inc. purchased a new position in Opko Health during the fourth quarter valued at $33,000. Bank of New York Mellon Corp lifted its position in Opko Health by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 1,661,535 shares of the biotechnology company’s stock valued at $5,001,000 after purchasing an additional 10,880 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its position in Opko Health by 4.3% during the third quarter. Wells Fargo & Company MN now owns 337,868 shares of the biotechnology company’s stock valued at $1,169,000 after purchasing an additional 13,905 shares in the last quarter. Institutional investors and hedge funds own 24.42% of the company’s stock.
About Opko Health (NASDAQ:OPK)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Recommended Story: Preferred Stock
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.